HER-2/neu oncogenic protein: Issues in vaccine development

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 37-45

  Disis, Mary L ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

HER 2 neu; Oncogenic protein; Peptide; Self protein; Tumor antigen; Vaccine

Indexed keywords

CANCER VACCINE; ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT VACCINE; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DRUG FORMULATION; HELPER CELL; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; ARTICLE; CLINICAL TRIAL; IMMUNOLOGY; NEOPLASM;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2; VACCINES, SYNTHETIC;

EID: 0030725551     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Nanda, N. K. and Sercarz, E. E., Induction of antiself-immunity to cure cancer, Cell, 82, 13-7, 1995.
2. Niehans, G. A., Singleton, T. P., Dykoski, D., and Kiang, D. T., Stability of HER-2/neu expression over time and at multiple metastatic sites, J. Natl. Cancer Inst., 85, 1230-1235, 1993.
3. Bargmann, C., Hung, M., and Weinberg, R., The neu oncogene encodes an epidermal growth factor receptor-related protein, Nature, 319, 226-230, 1986.
4. Coussens, L., Yang-Feng, T. L., Chen, Y. L. E., Gray, A., McGrath, J., Seeburg, P. H., Liberman, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science, 230, 1132-1139, 1985.
5. Lupu, R., Dickson, R., and Lippman, M., The role of erbB-2 and its ligands in growth control of malignant breast epithelium, J. Steroid Biochem. Mol. Biol., 43, 229-236, 1992.
6. Bacus, S. S., Stancovski, I., Huberman, E., Chin, D., Hurwitz, E., Mills, G. B., Ullrich, A., Sela, M., and Yarden, Y., Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells, Cancer Res., 52, 2580-2589, 1992.
7. Press, M., Cordon-Cardo, C., and Slamon, D., Expression of HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene, 5, 953-962, 1990.
8. Berchuck, A.,Kamel A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J., Dodge, R., Clarke-Pearson, D., and Marks, P., Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer, Cancer Res., 50, 4087-4091, 1990.
9. Berchuck, A., Rodriguez, G., Kinney, R. B., Soper, J. T., Dodge, R. K., Clarke-Pearson, D. L., and Bast, R. C., Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease, Am. J. Obstet. Gynecol., 15-21, 1991.
10. neu expression in human lung adenocarcinomas predicts shortened survival, Cancer Res., 50, 5184-5191, 1990.
11. Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., and McGuire, W., Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177-182, 1987.
12. Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazakil, I., Endou, Y., Tanaka, M., and Susaki, T., Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognisis in gastric cancer, Cancer Res., 51, 1034-1038, 1991.
13. Slamon, D., Godolphin, W., Jones, L., Holt, J., Wong, S., Keith, D., Levine, W., Stuart, S., Udove, J., Ullrich, A., and Press, M., Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707-712, 1989.
14. Allred, D., Clark, G., Tandon, A., Molina, R., Tormey, D., Osborne, C., Gilchrist, K., Mansour, E., Abeloff, M., and Eudey, L., HER-2/neu in node-negative breast cancer: prognostic significance of Overexpression influenced by the presence of in situ carcinoma, J. Clin. Oncol., 10, 599-605, 1992.
15. Rilke, F., Colnaghi, M., Cascinelli, N., Andreola, S., Baldini, M., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M., and Testori, A., Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors, Int. J. Cancer, 49, 44-49, 1991.
16. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., Moe, R., and Cheever, M. A., Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res., 54, 16-20, 1994.
17. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G., Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, J. Exp. Med., 181, 2109-2117, 1995.
18. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide, Proc. Natl. Acad. Sci., U.S.A., 92, 432-436, 1995.
19. Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., and Cheever, M. A., High titer HER-2/ neu protein specific antibody immunity can be de tected impatients with early stage breast cancer, J. Clin. Oncol., in press, 1997.
20. Katsumata, M., Okudaira, T., Samanta, A., Clark, D. P., Drebin, J. A., Jolicoeur, P., and Greene, M. I., Prevention of breast tumour development in vivo by downregulation of the p185neu receptor, Nature Med., 1, 644-648, 1995.
21. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L., Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see comments], J. Clin. Oncol., 14, 737-744, 1996.
22. Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., and Eshhar, Z., Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors, J. Immunol, 151, 6577-6582, 1993.
23. Moritz, D., Wels, W., Mattern, J., and Groner, B., Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells, Proc. Natl Acad. Sci. U.S.A., 91, 4318-4322, 1994.
24. Bernards, R., Destree, A., McKenzie, S., Gordon, E., Weinberg, R. A., and Panicali, D., Effective tumor immunotherapy directed against an oncogeneencoded product using a vacinnia virus vector, Proc. Natl. Acad. Sci. U.S.A., 84, 6854-6858, 1987.
25. Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., and Cheever, M. A., Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein, J. Immunol., 156, 3151-3158, 1996.
26. Sercarz, E. E., Lehmann, P. V., Ametani, A., Benichou, G., Miller, A., and Moudgil, K., Dominance and crypticity of T cell antigenic determinants, Annu. Rev. Immunol., 11, 729-766, 1993.
27. Cibotti, R., Kanellopoulos, J. M., Cabaniols, J. P., Halle-Panenko, O., Kosmatopoulos, K., Sercarz, E., and Kourilsky, P., Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants, Proc. Natl. Acad. Sci. U.S.A., 89, 416-420, 1992.
28. Arnon, R. and Van-Regenmortel, M. H., Structural basis of antigenic specificity and design of new vaccines, Faseb J., 6, 3265-3274, 1992.
29. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. U.S.A., 90, 3539-3543, 1993.
30. Reid, C. D., Stackpoole, A., Meager, A., and Tikerpae, J., Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating fac-tor and other cytokinesin the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow, J. Immunol., 149, 2681-2688, 1992.
31. Golumbek, P. T., Azhari, R., Jaffee, E. M., Levitsky, H. I., Lazenby, A., Leong, K., and Pardoll, D. M., Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design, Cancer Res., 53, 5841-5844, 1993.
32. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A., Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines, Blood, 88, 202-210, 1996.
33. Feller, D. and Cruz, D. L., Identifying antigenic T cell sites, Nature, 349, 720-721, 1991.
34. Roscoe, D. M., Jung, S. H., Benhar, I., Pai, L., Lee, B. K., and Pastan, I., Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin, Infect. Immunol, 62, 5055-5065, 1994.
35. Bisset, L. R. and Fierz, W., Using a neural network to identify potential HLA-DR1 binding sites within proteins, J. Mol. Recognit., 6, 41-48, 1993.
36. Ioannides, C. G., Ioannides, M. G., and O' Brian, C. A., T-cell recognition of oncogene products: a new strategy for immunotherapy, Mol. Carcinogen., 6, 77-82, 1992.
37. Lee, R. S., Grusby, M. J., Glimcher, L. H., Winn, H. J., and Auchincloss, H., Jr., Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo, J. Exp, Med., 179, 865-872, 1994.
38. Lin, Y., Langman, R., and Cohn, M., The priming of cytotoxic T-cell precursors is strictly helper T cell-dependent, Scand. J. Immunol., 35, 621-626, 1992.
39. Shirai, M., Pendleton, C. D., Ahlers, J., Takeshita, T., Newman, M., and Berzofsky, J. A., Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs, J. Immunol., 152, 549-556, 1994.
40. Leitzel, K., Teramoto, Y., Sampson, E., Mauceri, J., Langton, B., Demers, L., Podczaski, E., Harrey, H., Shambaugh, S., Volas, G., Weaver, S., and Lipton, A., Elevated soluble c-erb-2 antigen levels in the serum and effusions of a proportion of breast cancer patients, J. Clin. Oncol., 10,1436-1443, 1992.
41. Herrington, D. A., Clyde, D. F., Losonsky, G., Cortesia, M., Murphy, J. R., Davis, J., Baqar, S., Felix, A. M., Heimer, E. P., Gillessen, D., et al., Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites, Nature, 328, 257-259, 1987.
42. Etlinger, H. M., Felix, A. M., Gillessen, D., Heimer, E. P., Just, M., Pink, J. R., Sinigaglia, F., Sturchler, D., Takacs, B., Trzeciak, A., et al., Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum, J. Immunol., 140, 626-633, 1988.
43. Bourdette, D. N., Whitham, R. H., Chou, Y. K., Morrison, W. J., Atherton, J., Kenny, C., Liefeld, D., Hashim, G. A., Offner, H., and Vandenbark, A. A., Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides [published erratum appears in J. Immunol. 153(2), 910, 1994], J Immunol., 152, 2510-2519, 1994.
44. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Solheim, B. G., Soreide, O., Thorsby, E., and Gaudernack, G., Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation, Lancet, 346, 1399-1400, 1995.
45. Reece, J. C., Geysen, H. M., and Rodda, S. J., Mapping the major human T helper epitopes of tetanus toxin. The emerging picture, J. Immunol., 151, 6175-6184, 1993.
46. Disis, M. L., Grabstein, K. H., Sleath, P. R., and Cheever, M. A., Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide based vaccine, (submitted) 1997.